Ingevity (NGVT) Cash & Equivalents (2015 - 2026)

Ingevity (NGVT) has reported Cash & Equivalents for 12 consecutive years, with $97.4 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents rose 26.66% year-over-year to $97.4 million; the TTM figure through Jun 2026 stood at $97.4 million (up 26.66% YoY), while the FY2025 annual figure was $78.1 million, up 14.85% from the prior year.
• Cash & Equivalents advanced to $97.4 million in Q2 2026 per NGVT's latest filing, from $95.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $222.6 million in Q1 2022 and bottomed at $68.0 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $96.2 million across 5 years, with a median of $84.0 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 73.16% — and 2024, when it soared 60.36%.
• Ingevity's Cash & Equivalents stood at $76.7 million in 2022, then advanced by 25.03% to $95.9 million in 2023, then decreased by 29.09% to $68.0 million in 2024, then advanced by 14.85% to $78.1 million in 2025, then gained by 24.71% to $97.4 million in 2026.
• Business Quant data shows NGVT's Cash & Equivalents at $97.4 million in Q2 2026, $95.4 million in Q1 2026, and $78.1 million in Q4 2025.